Chlorogenic acid and kojic acid as anti-hyperpigmentation: in silico study
Pharmacy Reports · 2022
DOI: 10.51511/pr.23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacy Reports, 2022. Verfasst von I Made Agus Yudantara und 3 weiteren Autor:innen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hyperpigmentation is a skin problem caused by excessive melanin production due to continuous ultraviolet (UV) radiation. Kojic acid inhibiting melanin synthesis by tyrosinase enzyme is a prevalent treatment for hyperpigmentation. This study aims to determine the potential of chlorogenic acid and kojic acid as an anti-hyperpigmentation against tyrosinase using in silico molecular docking. The docking process involved optimizing chlorogenic acid and kojic acid structures, preparing tyrosinase protein (PDB ID: 5M8O), validating the molecular docking method, and docking of chlorogenic acid and kojic acid on tyrosinase. The binding energy of chlorogenic acid and kojic acid were -4.59 kcal/mol and -3.75 kcal/mol, while the binding energy of 0TR native ligand was -5.02 kcal/mol. The interaction of chlorogenic acid to tyrosinase involved ARG 321 and ARG 374 residues. The results suggest that chlorogenic acid and kojic acid has the potential as anti-hyperpigmentation agents through inhibition of the tyrosinase enzyme.
Zitieren
APA
Yudantara, I. M. A., Cahyani, N. K. N., Saputra, M. A. W., & Dewi, N. K. D. P. (2022). Chlorogenic acid and kojic acid as anti-hyperpigmentation: in silico study. Pharmacy Reports. https://doi.org/10.51511/pr.23
Vancouver
Yudantara IMA, Cahyani NKN, Saputra MAW, Dewi NKDP. Chlorogenic acid and kojic acid as anti-hyperpigmentation: in silico study. Pharmacy Reports. 2022. doi:10.51511/pr.23
BibTeX
@article{Yudantara2022,
author = {Yudantara, I Made Agus and Cahyani, Ni Ketut Nitya and Saputra, Made Agus Widiana and Dewi, Ni Kadek Diah Parwati},
title = {Chlorogenic acid and kojic acid as anti-hyperpigmentation: in silico study},
journal = {Pharmacy Reports},
year = {2022},
doi = {10.51511/pr.23}
}
EUVIMED